Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer biopharma analysts to hold analyst/industry conference call » 13:25
09/27/21
09/27
13:25
09/27/21
13:25
ANGN

Angion Biomedica

$10.17 /

+0.085 (+0.84%)

, ALPMY

Astellas Pharma

$17.15 /

+0.0505 (+0.30%)

Biopharmaceuticals…

Biopharmaceuticals Analysts discuss treatment for Delayed Graft Function-associated Acute Kidney Injury (DGF-AKI) on an Analyst/Industry conference call to be held on September 27 at 2 pm.

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.17 /

+0.085 (+0.84%)

ALPMY Astellas Pharma
$17.15 /

+0.0505 (+0.30%)

ANGN Angion Biomedica
$10.17 /

+0.085 (+0.84%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ALPMY Astellas Pharma
$17.15 /

+0.0505 (+0.30%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
ANGN Angion Biomedica
$10.17 /

+0.085 (+0.84%)

  • 05
    Feb
ANGN Angion Biomedica
$10.17 /

+0.085 (+0.84%)

Conference/Events
Oppenheimer biopharma analysts to hold analyst/industry conference call » 04:55
09/27/21
09/27
04:55
09/27/21
04:55
ANGN

Angion Biomedica

$10.09 /

-0.285 (-2.75%)

, ALPMY

Astellas Pharma

$17.15 /

+0.0505 (+0.30%)

Biopharmaceuticals…

Biopharmaceuticals Analysts discuss treatment for Delayed Graft Function-associated Acute Kidney Injury (DGF-AKI) on an Analyst/Industry conference call to be held on September 27 at 2 pm.

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.09 /

-0.285 (-2.75%)

ALPMY Astellas Pharma
$17.15 /

+0.0505 (+0.30%)

ANGN Angion Biomedica
$10.09 /

-0.285 (-2.75%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ALPMY Astellas Pharma
$17.15 /

+0.0505 (+0.30%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
ANGN Angion Biomedica
$10.09 /

-0.285 (-2.75%)

  • 05
    Feb
ANGN Angion Biomedica
$10.09 /

-0.285 (-2.75%)

Conference/Events
Oppenheimer biopharma analysts to hold analyst/industry conference call » 15:44
09/23/21
09/23
15:44
09/23/21
15:44
ANGN

Angion Biomedica

$10.45 /

+0.21 (+2.05%)

, ALPMY

Astellas Pharma

$17.02 /

-0.22 (-1.28%)

Biopharmaceuticals…

Biopharmaceuticals Analysts discuss treatment for Delayed Graft Function-associated Acute Kidney Injury (DGF-AKI) on an Analyst/Industry conference call to be held on September 27 at 2 pm.

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.45 /

+0.21 (+2.05%)

ALPMY Astellas Pharma
$17.02 /

-0.22 (-1.28%)

ANGN Angion Biomedica
$10.45 /

+0.21 (+2.05%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ALPMY Astellas Pharma
$17.02 /

-0.22 (-1.28%)

06/29/21 Jefferies
Astellas Pharma downgraded to Hold from Buy at Jefferies
10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
ANGN Angion Biomedica
$10.45 /

+0.21 (+2.05%)

  • 05
    Feb
ANGN Angion Biomedica
$10.45 /

+0.21 (+2.05%)

Conference/Events
Angion Biomedica to host research and development virtual day » 09:55
09/20/21
09/20
09:55
09/20/21
09:55
ANGN

Angion Biomedica

$10.12 /

-0.45 (-4.26%)

Research and Development…

Research and Development Virtual Day to be held on September 20 at 10 am. Webcast Link

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.12 /

-0.45 (-4.26%)

ANGN Angion Biomedica
$10.12 /

-0.45 (-4.26%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$10.12 /

-0.45 (-4.26%)

  • 05
    Feb
ANGN Angion Biomedica
$10.12 /

-0.45 (-4.26%)

Conference/Events
Angion Biomedica to host research and development virtual day » 04:55
09/20/21
09/20
04:55
09/20/21
04:55
ANGN

Angion Biomedica

$10.57 /

-0.38 (-3.47%)

Research and Development…

Research and Development Virtual Day to be held on September 20 at 10 am. Webcast Link

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

  • 05
    Feb
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

Over a month ago
Conference/Events
Angion Biomedica to host research and development virtual day » 17:38
09/17/21
09/17
17:38
09/17/21
17:38
ANGN

Angion Biomedica

$10.57 /

-0.38 (-3.47%)

Research and Development…

Research and Development Virtual Day to be held on September 20 at 10 am. Webcast Link

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

  • 05
    Feb
ANGN Angion Biomedica
$10.57 /

-0.38 (-3.47%)

Earnings
Angion Biomedica reports Q2 EPS (58c), consensus (69c) » 16:43
08/12/21
08/12
16:43
08/12/21
16:43
ANGN

Angion Biomedica

$10.83 /

-2.335 (-17.74%)

Reports Q2 revenue…

Reports Q2 revenue $540,000, consensus $470,000. "I'm excited to announce we are pulling forward the planned release of topline data from the ANG-3777 Phase 3 trial in transplant-associated acute kidney injury, also known as delayed graft function (DGF), to early in the fourth quarter of 2021 because data cleaning for the clinical trial database is being completed faster than expected. We now expect the Phase 3 DGF trial to be the next data release from the ANG-3777 program," said Jay Venkatesan, Angion's president and CEO. "We are also very pleased with the results we announced last week from the Phase 1 ANG-3070 healthy volunteer study. These data, particularly the side effect profile seen in the Phase 1 study and the ability to achieve drug exposure in humans exceeding exposures in which activity was demonstrated in animal models, solidify our belief that ANG-3070 is a potentially best-in-class oral therapy for the treatment of fibrosis."

ShowHide Related Items >><<
ANGN Angion Biomedica
$10.83 /

-2.335 (-17.74%)

ANGN Angion Biomedica
$10.83 /

-2.335 (-17.74%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$10.83 /

-2.335 (-17.74%)

  • 05
    Feb
ANGN Angion Biomedica
$10.83 /

-2.335 (-17.74%)

Over a quarter ago
On The Fly
Fly Intel: After-Hours Movers » 18:25
06/29/21
06/29
18:25
06/29/21
18:25
POWW

AMMO

$8.81 /

+0.285 (+3.35%)

, VOXX

Voxx

$13.65 /

-0.4 (-2.85%)

, CYT

Cyteir Therapeutics

$19.90 /

+0.2 (+1.02%)

, QUMU

Qumu

$3.83 /

+0.13 (+3.51%)

, AVAV

AeroVironment

$110.20 /

-0.58 (-0.52%)

, ALT

Altimmune

$15.90 /

-0.4 (-2.45%)

, ANGN

Angion Biomedica

$14.31 /

+0.02 (+0.14%)

, REPX

Riley Exploration

$37.33 /

+0.51 (+1.39%)

, GDYN

Grid Dynamics

$17.54 /

-0.58 (-3.20%)

, CERE

Cerevel Therapeutics

$29.57 /

+17 (+135.24%)

, MDB

MongoDB

$383.51 /

-5.495 (-1.41%)

Check out this evening's…

ShowHide Related Items >><<
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

REPX Riley Exploration
$37.33 /

+0.51 (+1.39%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

04/22/21
Fly Intel: Top five analyst initiations
04/22/21 Lake Street
AMMO initiated with a Buy at Lake Street
04/08/21 Roth Capital
AMMO initiated with a Buy at Roth Capital
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

06/29/21 DA Davidson
Voxx initiated with a Buy at DA Davidson
CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
06/11/21 Craig-Hallum
Qumu downgraded to Hold from Buy at Craig-Hallum
02/12/21 Lake Street
Synacor downgraded to Hold from Buy at Lake Street
AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

06/23/21 Canaccord
AeroVironment investors focus on upcoming results and potential, says Canaccord
01/15/21 Stifel
AeroVironment downgraded to Hold from Buy at Stifel
01/14/21 Alembic Global
AeroVironment upgraded to Overweight from Neutral at Alembic Global
01/14/21 Baird
AeroVironment upgraded to Outperform after Arcturus deal at Baird
ALT Altimmune
$15.90 /

-0.4 (-2.45%)

06/18/21 Piper Sandler
CureVac data 'leaves the spot open' for Arcturus, says Piper Sandler
06/16/21 JMP Securities
Altimmune price target raised to $53 from $45 at JMP Securities
06/16/21 H.C. Wainwright
H.C. Wainwright says Altimmune has 'potential blockbuster indication' in obesity
06/16/21 Piper Sandler
Altimmune weight loss data 'outstanding,' says Piper Sandler
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
REPX Riley Exploration
$37.33 /

+0.51 (+1.39%)

06/01/21 Truist
Riley Exploration initiated with a Buy at Truist
06/01/21 Truist
Riley Exploration initiated with a Buy at Truist
04/08/21
Fly Intel: Top five analyst initiations
04/08/21 Roth Capital
Riley Exploration initiated with a Buy at Roth Capital
GDYN Grid Dynamics
$17.54 /

-0.58 (-3.20%)

05/03/21 Cantor Fitzgerald
Grid Dynamics assumed with an Overweight at Cantor Fitzgerald
03/08/21 Northland
Grid Dynamics price target raised to $17 from $11 at Northland
03/05/21 Cowen
Grid Dynamics price target raised to $17 from $14 at Cowen
12/16/20 Canaccord
Grid Dynamics price target raised to $15 from $11 at Canaccord
CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
11/23/20 Jefferies
Cerevel Therapeutics initiated with a Buy at Jefferies
11/09/20
Fly Intel: Top five analyst initiations
MDB MongoDB
$383.51 /

-5.495 (-1.41%)

06/04/21 Canaccord
MongoDB more upside likely on tap, says Canaccord
06/04/21 Needham
MongoDB price target raised to $415 from $409 at Needham
06/04/21 Mizuho
MongoDB price target raised to $300 from $265 at Mizuho
06/04/21 UBS
MongoDB price target lowered to $300 from $325 at UBS
VOXX Voxx
$13.65 /

-0.4 (-2.85%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

GDYN Grid Dynamics
$17.54 /

-0.58 (-3.20%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

  • 30
    Jun
  • 02
    Jul
  • 01
    Jul
  • 18
    Jun
  • 12
    Mar
  • 05
    Feb
  • 27
    Jan
  • 01
    Dec
  • 14
    Jul
ALT Altimmune
$15.90 /

-0.4 (-2.45%)

VOXX Voxx
$13.65 /

-0.4 (-2.85%)

QUMU Qumu
$3.83 /

+0.13 (+3.51%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CYT Cyteir Therapeutics
$19.90 /

+0.2 (+1.02%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

AVAV AeroVironment
$110.20 /

-0.58 (-0.52%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ALT Altimmune
$15.90 /

-0.4 (-2.45%)

VOXX Voxx
$13.65 /

-0.4 (-2.85%)

POWW AMMO
$8.81 /

+0.285 (+3.35%)

MDB MongoDB
$383.51 /

-5.495 (-1.41%)

CERE Cerevel Therapeutics
$29.57 /

+17 (+135.24%)

Hot Stocks
Angion Biomedica ALI-201 trial did not meet primary, secondary endpoints » 16:18
06/29/21
06/29
16:18
06/29/21
16:18
ANGN

Angion Biomedica

$14.31 /

+0.02 (+0.14%)

Angion Biomedica…

Angion Biomedica announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome, or ARDS, did not meet the primary or secondary efficacy endpoints. The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia. The ALI-201 study was a small exploratory Phase 2 double-blind, randomized, and placebo-controlled trial conducted in Brazil to evaluate the safety and efficacy of four doses of ANG-3777 in the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to ARDS. The primary endpoint of the trial was survival free from the need for mechanical ventilation or dialysis at 28 days. The active arm of the trial did not show a statistically significant difference over the standard of care arm. A total of 120 patients were randomized 1:1 in the trial, with 59 patients in the active treatment arm and 61 patients in the standard of care arm. The number of adverse events, serious adverse events, and fatal events reported in ALI-201 were slightly higher for those subjects in the active treatment arm compared to those in the standard of care control arm, although no new or unexpected safety signals resulted from the trial. None of the fatal events in this trial of advanced COVID-19 patients were attributed by study investigators to either ANG-3777 or standard of care in the control arm. The company expects to report data from the ANG-3777 Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, by the end of 2021. The company also expects to report data from the ANG-3777 Phase 2 proof of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery in the second half of 2021. "We were pleased to be part of the attempt to help patients severely ill with COVID-19 and extend our deepest gratitude to the patients, their families, investigators, and site staff who participated in this study," commented Jay Venkatesan, Angion's president and CEO. "With the increasing availability of approved COVID-19 vaccines and the widespread assumption vaccines will reduce infection rates around the world, we will not continue the development of this COVID-19 program. Based on the promising activity of ANG-3777 in multiple animal models of lung injury, we will continue to evaluate the clinical development of ANG-3777 for acute lung injury populations."

ShowHide Related Items >><<
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

  • 05
    Feb
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

Hot Stocks
Angion Biomedica ALI-201 trial did not meet primary, secondary endpoints  16:16
06/29/21
06/29
16:16
06/29/21
16:16
ANGN

Angion Biomedica

$14.31 /

+0.02 (+0.14%)

 
ShowHide Related Items >><<
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Cowen
Angion Biomedica initiated with an Outperform at Cowen
03/02/21 Oppenheimer
Angion Biomedica initiated with an Outperform at Oppenheimer
03/02/21 Stifel
Angion Biomedica initiated with a Buy at Stifel
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

  • 05
    Feb
ANGN Angion Biomedica
$14.31 /

+0.02 (+0.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.